VMM concepção e planejamento do projeto e pesquisa, obtenção e análise dos dados, redação. PSF concepção e planejamento do projeto e pesquisa, análise estatística, interpretação dos dados, redação e revisão crítica. MFR concepção e planejamento do projeto de pesquisa. HCCF obtenção de dados e redação. RFS interpretação de dados, redação e revisão crítica. RCMAS concepção e planejamento do projeto de pesquisa, análise e interpretação dos dados, redação e revisão crítica. Descritores: Hepatite C; Fígado; Transplante.
Introduction
Cirrhosis due to hepatitis C virus (HCV) infection is the leading indication for liver transplantation in adults in the Western countries (1) .However, the recurrence of HCV infection following the transplant is universal, and approximately 30% of these patients develop cirrhosis within five years (2) . These data contradict the natural history of hepatitis C in non-transplant patients, in which about 10 to 20% of the patients will develop cirrhosis after many years of infection (3) (4) , thus indicating the severity of such infection in the liver transplant setting. Recognizing characteristics both in the receptor and in the donor, which affected the natural history of HCV infection following liver transplant can have a great impact in the development of strategies aimed at minimizing the problem. Even though some clinical parameters have already been identified, there are not still any reliable means of recognizing which patients will have a rapid progression of the hepatic fibrosis after the transplant. Among the variables associated with the progression of the disease after the transplant, the following ones have already been mentioned: non-Caucasian ethnicity, high HCV viral load at the moment of the transplant, and cumulative dose of steroids (2) .
The antiviral HCV treatment for patients who were subjected to liver transplant is, on the one hand, a priority, regardless of the state of the fibrosis (5) . On the other hand, it is a challenge considering its adverse events in this group of patients. Until recently, the standard therapy involving interferon alfa (IFN) or Pegylated interferon alfa (PegIFN) associated with ribavirin (RBV) was the only one recommended, but the success rates were reported as inferior to the ones registered in non-immunosuppressed patients, and a low tolerance was also identified (6) . Currently, the antiviral therapy for hepatitis C is going through important changes, and the new drugs available, such as the DAAs (direct-acting antivirals) may represent more safety, and efficiency scheduled therapy. These new drugs may be even administered to decompensated cirrhotic patients waiting for liver transplantation, although there are not widely available data for patients with Child-Pugh C cirrhosis (5) . Preliminary results from the DAAs therapy for liver transplanted patients are being published (7) (8) (9) (10) (11) , but larger and more detailed studies that have already been concluded involving these patients are necessary before any of these new drugs are safely recommended for the different clinical situations that emerge after liver transplantation (12) . The aim of the present study was to describe the recurrence of HCV infection after liver transplantation, and the sustained virological response to interferon-based therapy in a cohort of liver transplant patients.
Patients and Methods
All medical records of HCV infected patients subjected to liver transplantation from 1998 to 2010 at the Hospital de Base, the University Hospital at the Medical School of Sao Jose do Rio Preto, Sao Paulo, were analyzed. Patients with at least one liver biopsy after the transplantation were included. HCV recurrence after liver transplantation was defined by the positivity of serum HCV RNA and histological evidence of hepatitis at liver biopsy.
The first liver biopsy with histological parameters of viral damage was considered for diagnosis of time of hepatitis recurrence. The study excluded those patients without post-transplant liver biopsy or with medical records inconsistent or missing data.
Retrospective cohort study
The following clinical and laboratory variables were analyzed: demographic data of the receptor (age, gender) and the donor (age), laboratory data regarding the hepatic function, the HCV infection genotype), immunosuppression therapy, and time for hepatitis recurrence defined as the time from transplant to the date of histological recurrence of hepatitis C.
Histological analysis
All post-transplant biopsies were analyzed by a single experienced pathologist according to the Metavir classification criteria (13) . Protocol liver biopsies were performed yearly or for elevations in serum transaminase levels, and according to patient compliance.
Antiviral therapy
Patients subjected to antiviral therapy received weekly subcutaneous injections of IFN alfa or PegIFN alfa 2a or 2b both combined with daily doses of oral ribavirin. Treatment efficacy was defined as the presence of a sustained virological response (SVR), e.g., HCV RNA undetectable at post-treatment week 24. The antiviral therapy efficacy was analyzed under the intention--to-treat principle.
Statistical analysis
Descriptive analysis included absolute and relative frequencies for categorical variables, and means, medians, standard deviation, and variation for continuous variables. The normal distribution of the continuous variables was verified by analyzing the skewness and kurtosis and applying the Kolmogorov-Smirnov test of normality. The Student t-test was used to compare groups of continuous variables and the chi-square test or Fisher Exact test for categorical variables. Disease-free survival was defined as the time from the transplant to the date of histological recurrence of hepatitis C or the date of last liver biopsy. Survival analysis was performed using Kaplan-Meier estimator method. P value< 0.05 was considered significant. The statistical analysis was conducted through the IBM SPSS Statistics software for Windows, version 18 (IBM Corporation, NY, USA).
Ethical considerations
The study respected all ethics precepts specified by the Resolution 466/12 of the National Health Council. The study protocol was submitted to the local Ethics Committee (CEP/FAMERP) receiving authorization under protocol number 33815/2012.
Results
From the 147 liver transplanted patients with HCV during the period of the study, 80 were included in the study. Those without a liver biopsy after transplantation or whose records lacked information was excluded (67 patients). The clinical and demographic characteristics are in Table 1 . 
HCV recurrence after liver transplantation
Histological recurrence of hepatitis C occurred rapidly following liver transplantation (Table 2 ). There was histological evidence of hepatitis C in 40 of 56 patients (71%) subjected to liver biopsy within the first 6 months following liver transplantation. *The first liver biopsy with histological parameters of viral damage was considered for diagnosis of time of hepatitis recurrence. **Number of patients with histological recurrence in relation to total number of liver biopsies performed in the period; the total number of performed liver biopsies excludes those from patients who had already histological recurrence in the previous period. LT, liver transplantation.
Disease-free survival analysis
The median follow-up period from liver transplantation to the date of histological recurrence of hepatitis C or the date of last liver biopsy was 9.7 months (the range was from 0.3 to 62 months). Disease-free survival curve is shown in figure 2 . Median disease-free survival was 11.6 months. Disease-free survival curve is shown in figure 1 . 
Antiviral Treatment
Between 1998 and 2010, thirty-five patients were subjected to antiviral treatment with IFN+RBV (n = 12) or PegIFN+RBV (n = 23). The baseline characteristics of the patients submitted to antiviral treatment are in Table 3 . The global SVR rate was 44%. Cytopenia was the main side effect: anemia, 79%; leukopenia, 68%; thrombocytopenia, 64%. Blood transfusions were necessary in 30% of the patients.
Comparative analyses between SVR group and non-responders group to antiviral therapy are in Table 4 . 
Discussion
In this study, the HCV hepatitis recurrence occurred shortly after liver transplantation. It has been shown in the literature HCV reinfection of the liver transplant and hepatitis in 50% of the patients after one year, and 100% after five years of follow-up (2) . In accordance with these data, it was observed in the present study hepatitis recurrence about twelve-month post transplantation for half of the patients. The liver biopsies were indicated yearly or for elevations in serum transaminase levels and according to patient compliance; it is worth mentioning at times some patients did not agree with liver biopsy, or in some instances, it was impossible due to comorbid conditions. However, it is important to note the rigorous histology analysis performed by a single experienced pathologist allowed recurrence of hepatitis C to be diagnosed when only histological criteria of viral damage were present, excluding those with histological findings to other situations such as drug-induced hepatitis or graft rejection. The natural history of cirrhosis caused by hepatitis C after liver transplant is unknown. An important study (14) tried to determine predictive factors for clinical decompensation, retransplantation, and mortality rates. All the patients were infected by HCV genotype 1b. The variables included were: histological activity rates after the transplant, hepatic function tests, age, gender, and maintenance immunosuppression. The research has shown that, in case a retransplantation is being considered, it must be conducted very early, since a decompensation may occur. Clinical decompensation was defined as the occurrence of ascites with or without peripheral edema, hydrothorax, varicose veins bleeding, spontaneous bacterial peritonitis, or encephalopathy during the follow-up. Studies on the evolution of cirrhosis in the graft agree upon the fact that the recurrence of HCV infection causes hepatic failure in a great amount of patients, and the progression period is shorter than in the non-immunosuppressed patients (15) . Several risk factors for development of recurrent chronic HCV after liver transplantationhavebeen discussed, including recipient and donor factors. Although the HCV genotype and the appearance of quasispecies were at times reported as relevant factors regarding the recurrence of HCV. The lack of sufficient sensibility and specificity of the viral factors does not allow them to be used to determine which patients should be subjected to liver transplant and which ones should be given a preventive antiviral therapy. This is also true for the variables regarding the receptor, including age, gender, and ethnicity (15) . Among donor factors, it is important to emphasize that several studies confirm the relation between the advanced donor age with a earlier and more severe histological progression of the HCV recurrence and a decrease in survival of recipients (16) .Even though the median age of liver donor in the present study was 34.5 years, there was a considerable variability with the maximum age being 67 years. The treatment in the immediate postoperative period is tolerated, but the efficiency is normally unsatisfactory, according to the literature. Preventive therapy refers to the antiviral therapy that begins within two to eight weeks after the transplant, when the viral load is low and there are no histological damages, and it is not adopted in the routine practice. The factors that contribute to low response rates among the receptors of liver transplant include: bone marrow suppression by IFN, when used in combination with immunosuppression drugs, and low tolerance to ribavirin (17) . Other factors associated with low responses are: genotype 1, absence of premature virological response, male gender, high basal viral load and resistance to insulin (17) . In the present study, antiviral therapy yielded a low SVR rate; data also noticed a considerable difference in the SVR rates when HCV genotypes 1 and non-genotype 1 was compared, which confirmed the data provided by the literature (18) . In relation to age, there was a trend towards higher rates of SVR in younger patients but this difference did not reach statistical significance; the comparative analysis of SVR according to gender did not show any relevant differences. Side effects were frequent in this study. The most important side effect was cytopenia and approximately one-third of patients required blood transfusion. Similar Results were reported by other groups (19) (20) (21) . In a revision about treatment (21) , almost a third of the patients had their treatment interrupted due to this side effect, and the others needed a dose reduction to increase the tolerance. Some authors defend (17) that the antiviral therapy must be offered to all patients as soon as histological evidence of HCV relapses is detected. Another important consideration is that, in case a re-transplantation is being discussed, a prophylactic antiviral therapy would be the most effective measure in order to reduce the progression of the disease after the transplantation, and this option is not available in clinical practice. The new antiviral treatment for HCV was available for some countries (5, 6) and it is very likely to increase the tolerance, and the efficiency for patients subjected to liver transplant as well (22) (23) (24) . More evidence produced by real-life studies is still to be published involving a large number of patients in this specific group and is being widely anticipated (25) . Certainly soon this treatment will be started earlier for these patients due to better tolerance and efficacy. It is also possible to anticipate this therapeutic measure will potentially prevent the progression to cirrhosis due to HCV recurrence after liver transplantation and subsequently increase survival for this group of patients.
Conclusion
Hepatitis C recurrence in liver transplant recipients occurred within a short period of time. The antiviral therapy was poorly tolerated and yielded a low SVR rate. This data emphasized the need for new drugs, more effective and with a better safety profile, in thesearch for the eradication of the HCV both before and after the liver transplantation.
